PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2026Journal of Clinical Oncology0 citations

Tislelizumab and POFI as First-Line Treatment for Advanced Gastric Cancer

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023).

View Full Paper

Authors

JCJ Q ChenRLRongbo LinLSLiyu Su

Discussion

Loading...

Member takes

Overview

Single-arm trial evaluates safety and efficacy of Tisle plus POFI in advanced gastric cancer, suggesting potential effectiveness.

Key Points

  • This study aims to evaluate the safety and efficacy of Tisle combined with POFI as a first-line treatment for advanced gastric cancer.
  • Single-center, single-arm phase I/II trial enrolling treatment-naïve patients aged 18-75 with measurable lesions and ECOG PS 0-1.
  • Participants received POFI regimen along with Tisle therapy every two weeks.
  • Primary endpoint was the objective response rate per RECIST 1.1.
  • Confirmed objective response rate was 76.6% (36/47).
  • Median overall survival was 16.0 months (95% CI: 12.4, 23.0).
  • Common grade 3/4 adverse events included neutropenia (53.2%) and leukopenia (27.7%).
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a192ea9fab5b468c4417e4chttps://doi.org/10.1200/jco.2026.44.16_suppl.4030
Ask AI
Helpful
Bookmark
Share
View Full Paper